OrbiMed Advisors XFOR Position
Exited4-Fund ConvergenceOrbiMed Advisors exited their position in X4 Pharmaceuticals, Inc (XFOR) in Q2 2025, after holding the stock for 10 quarters.
The position was first reported in Q1 2023 and has been tracked across 10 quarterly 13F filings.
XFOR is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Mavorixafor in 532 days (Sep 30, 2027), making the timing of OrbiMed's position particularly relevant.
About X4 Pharmaceuticals, Inc
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
Full company profile →Short Interest
3.9%
5.8 days to cover
OrbiMed Advisors XFOR Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q2 2025 | Exited | 0 | -6,776,515 | $0 |
| Q1 2025 | Decreased | 6,776,515 | -357,000 | $1.6M |
| Q4 2024 | Held | 7,133,515 | — | $5.2M |
| Q3 2024 | Held | 7,133,515 | — | $4.8M |
| Q2 2024 | Held | 7,133,515 | — | $4.1M |
| Q1 2024 | Held | 7,133,515 | — | $9.9M |
| Q4 2023 | Held | 7,133,515 | — | $6.0M |
| Q3 2023 | Held | 7,133,515 | — | $7.8M |
| Q2 2023 | Increased | 7,133,515 | +1,315,789 | $13.8M |
| Q1 2023 | New | 5,817,726 | +5,817,726 | $5.1M |
Frequently Asked Questions
Does OrbiMed Advisors own XFOR?
No. OrbiMed Advisors exited their position in X4 Pharmaceuticals, Inc (XFOR) in Q2 2025. They previously held the stock for 10 quarters.
How many hedge funds own XFOR?
4 specialist biotech hedge funds currently hold XFOR, including Perceptive Advisors, Deep Track Capital, BVF Partners and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy XFOR?
OrbiMed Advisors's position in XFOR was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's XFOR position increasing or decreasing?
OrbiMed Advisors completely exited their XFOR position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
XFORCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →